Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

APSAC

Fig. 4. Fibrinolytic system where SCUPA is single-chain urokinase plasminogen activator rTPA is recombinant tissue plasminogen activator APSAC is acylated plasminogen streptokinase activator complex SK is streptokinase and UK is urokinase. Fig. 4. Fibrinolytic system where SCUPA is single-chain urokinase plasminogen activator rTPA is recombinant tissue plasminogen activator APSAC is acylated plasminogen streptokinase activator complex SK is streptokinase and UK is urokinase.
APSAC = acylated plasminogen streptokinase activator complex. [Pg.180]

In acylated form, the APSAC offers a prolonged half-life (105 min), greater lysis potency, and less systemic lytic state. APSAC is used at 30 U (30 mg) by iv injection. [Pg.144]

Aprotic polar polymers, 23 733 APSAC-anistreplase, 5 175, 177-178 molecular formula and structure, 5 172t Aptamers, 17 621, 631-632... [Pg.66]

Anistreplase (anisoylated plasminogen streptokinase activator complex APSAC) consists of a complex of purified human plasminogen and bacterial streptokinase that has been acylated to protect the enzyme s active site. When administered, the acyl group spontaneously hydrolyzes, freeing the activated streptokinase-proactivator complex. This product (recently discontinued in the USA) allows for rapid intravenous injection, greater clot selectivity (ie, more activity on plasminogen associated with clots than on free plasminogen in the blood), and more thrombolytic activity. [Pg.766]

Clinical trials One of the trials (ISIS-3) showed that streptokinase plus aspirin performed as well as recombinant tissue-type plasminogen activator (rt-PA) or complex formulations of streptokinase such as anistreplase (APSAC). The GUSTO trial showed a small advantage for the much more expensive t-PA over streptokinase, but with a significantly higher risk of hemorrhagic stroke. Nine clinical trials—each containing over 1000 patients with suspected acute myocardial infarction—... [Pg.774]

Anistreplase (anisoylated plasminogen streptokinase activator complex, APSAC), is the plasminogen-streptokinase complex (above) in which the enzyme centre that converts plasminogen to plasmin is protected from deactivation, so prolonging its action. [Pg.578]

Been M, de Bono DP, Muir AL, Boulton FE, Fears R, Standring R, Ferres H. Clinical effects and kinetic properties of intravenous APSAC—anisoylated plasminogen-streptokinase activator complex (BRL 26921) in acute myocardial infarction. Int J Cardiol 1986 11(1) 53-61. [Pg.3406]

AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction preliminary report of a placebo-controlled clinical trial. Lancet 1988 l(8585) 545-9. [Pg.3407]

Le SP, Chatterjee K, Wolfe CL. Adult respiratory distress syndrome following thrombolytic therapy with APSAC for acute myocardial infarction. Am Heart J 1992 123(5) 1368-9. [Pg.3408]

Anisoylated plasminogen streptokinase activator complex (APSAC, anistreplase)... [Pg.310]

Synonym APSAC Trade names Eminase Iminase Indications Acute myocardial infarction Category Fibrinolytic Half-life 70-120 minutes... [Pg.39]

Animal experiments corroborated that, compared with the nonacylated complex, a smaller quantity of the acylated plasmin-streptokinase-activator complex (APSAC) was required to obtain thrombolysis [35]. [Pg.65]

See other pages where APSAC is mentioned: [Pg.67]    [Pg.180]    [Pg.180]    [Pg.180]    [Pg.144]    [Pg.144]    [Pg.144]    [Pg.310]    [Pg.310]    [Pg.311]    [Pg.582]    [Pg.621]    [Pg.584]    [Pg.623]    [Pg.180]    [Pg.180]    [Pg.67]    [Pg.310]    [Pg.310]    [Pg.311]    [Pg.356]    [Pg.420]    [Pg.65]    [Pg.214]    [Pg.3402]    [Pg.121]   
See also in sourсe #XX -- [ Pg.579 ]

See also in sourсe #XX -- [ Pg.297 ]

See also in sourсe #XX -- [ Pg.308 , Pg.309 , Pg.310 ]



SEARCH



APSAC (anistreplase anisoylated

APSAC (anistreplase anisoylated plasminogen streptokinase

© 2024 chempedia.info